Reversing age-related damage in retinal cells to improve vision
Partial epigenetic reprogramming of retinal pigment cells in age-related degeneration, dysfunction, and injury
This study is exploring a way to help aging eye cells work better again, which could improve vision for people with age-related macular degeneration (AMD).
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Schepens Eye Research Institute NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10864038 on NIH RePORTER |
What this research studies
This research investigates how partial epigenetic reprogramming can restore the function of retinal pigment epithelial (RPE) cells that deteriorate with age, contributing to age-related macular degeneration (AMD). The approach involves using specific factors to induce changes in the cells' genetic expression, potentially reversing damage and improving vision. The study will utilize various techniques to assess the effects of this reprogramming on cell function and structure in mouse models, aiming to provide insights that could lead to new treatments for AMD.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing early signs of age-related macular degeneration.
Not a fit: Patients with advanced or exudative forms of age-related macular degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that restore vision in patients suffering from age-related macular degeneration.
How similar studies have performed: Previous research has shown promising results with similar epigenetic reprogramming approaches in animal models, indicating potential for success in this area.
Where this research is happening
Boston, United States
- Schepens Eye Research Institute — Boston, United States (Active)
Researchers
- Principal investigator: Hu, Zhengping — Schepens Eye Research Institute
- Study coordinator: Hu, Zhengping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.